Skip to main content
SpringerLink
Log in
Book cover

Les cancers ovariens pp 405–415Cite as

Traitement médical des rechutes (récidives) précoces

  • Chapter

  • 328 Accesses

Part of the book series: Abord clinique ((ONCOLPRAT))

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Rustin GJ, Nelstrop AE, Tuxen MK et al. (1996) Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7: 361–4

    CAS  PubMed  Google Scholar 

  2. Wernyj RP, Morin PJ (2004) Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel. Drug Resist Updat 7: 227–32

    CAS  PubMed  Google Scholar 

  3. Yusuf RZ, Duan Z, Lamendola DE et al. (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3: 1–19

    Article  CAS  PubMed  Google Scholar 

  4. Rose PG, Mossbruger K, Fusco N et al. (2003) Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum-and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 88: 17–21

    CAS  PubMed  Google Scholar 

  5. Horowitz NS, Hua J, Gibb RK et al. (2004) The role of topotecan for extending the platinumfree interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol 94: 67–73

    Article  CAS  PubMed  Google Scholar 

  6. Mizutani Y, Nakanishi H, Li YN et al. (2004) Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522. J Urol 172: 1474–9

    Article  CAS  PubMed  Google Scholar 

  7. Wang G, Zheng WT, Xiao P et al. (2004) [Effects of mifepristone on the proliferation, apoptosis, and cisplatinum (DDP) sensitivity of chemo-resistant human ovarian cancer cells]. Ai Zheng 23: 406–11

    CAS  PubMed  Google Scholar 

  8. Markman M, Webster K, Zanotti K et al. (2004) Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. Gynecol Oncol 94: 404–8

    CAS  PubMed  Google Scholar 

  9. Funato T (2004) Utility of antioncogene ribozymes and antisense oligonucleotides in reversing drug resistance. Methods Mol Med 106: 215–34

    Google Scholar 

  10. Saga Y, Hashimoto H, Yachiku S et al. (2004) Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors. Int J Urol 11: 407–15

    CAS  PubMed  Google Scholar 

  11. Ozols RF, Ostchega Y, Curt G et al. (1987) High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 5: 197–201

    CAS  PubMed  Google Scholar 

  12. Trimble EL, Adams JD, Vena D et al. (1993) Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11: 2405–10

    CAS  PubMed  Google Scholar 

  13. Thigpen JT, Blessing JA, Olt G et al. (2003) Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 90: 581–6

    Article  CAS  PubMed  Google Scholar 

  14. Markman M, Zanotti K, Webster K et al. (2003) Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol 91: 573–6

    CAS  PubMed  Google Scholar 

  15. Markman M, Kennedy A, Webster K et al. (2000) Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78: 369–72

    CAS  PubMed  Google Scholar 

  16. Rose PG, Maxson JH, Fusco N et al. (2001) Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 82: 323–8

    CAS  PubMed  Google Scholar 

  17. Gordon AN, Fleagle JT, Guthrie D et al. (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312–22

    CAS  PubMed  Google Scholar 

  18. Wilailak S, Linasmita V (2004) A study of pegylated liposomal Doxorubicin in platinumrefractory epithelial ovarian cancer. Oncology 67: 183–6

    Article  CAS  PubMed  Google Scholar 

  19. Vasey PA, McMahon L, Paul J et al. (2003) A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer. Br J Cancer 89: 1843–8

    Article  CAS  PubMed  Google Scholar 

  20. Rischin D, Phillips KA, Friedlander M et al. (2004) A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. Gynecol Oncol 93: 417–21

    Article  CAS  PubMed  Google Scholar 

  21. Rose PG, Blessing JA, Mayer AR et al. (1998) Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 16: 405–10

    CAS  PubMed  Google Scholar 

  22. Markman M, Webster K, Zanotti K et al. (2003) Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 90: 593–6

    Article  CAS  PubMed  Google Scholar 

  23. Piura B, Rabinovich A (2004) Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma. Eur J Gynaecol Oncol 25: 449–52

    CAS  PubMed  Google Scholar 

  24. Markman M, Blessing JA, Moore D et al. (1998) Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 69: 226–9

    CAS  PubMed  Google Scholar 

  25. Keldsen N, Havsteen H, Vergote I et al. (2003) Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. Gynecol Oncol 88: 118–22

    Article  CAS  PubMed  Google Scholar 

  26. Scarfone G, Villa A, Parazzini F et al. (1999) A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy. Tumori 85: 217–9

    CAS  PubMed  Google Scholar 

  27. Bodurka DC, Levenback C, Wolf JK et al. (2003) Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 21: 291–7

    Article  PubMed  Google Scholar 

  28. Hasan J, Jayson GC (2003) Oral melphalan as a treatment for platinum-resistant ovarian cancer. Br J Cancer 88: 1828–30

    Article  CAS  PubMed  Google Scholar 

  29. Fracasso PM, Blessing JA, Morgan MA et al. (2003) Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. J Clin Oncol 21: 2856–9

    Article  CAS  PubMed  Google Scholar 

  30. Dieras V, Bougnoux P, Petit T et al. (2002) Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/-taxane-pretreated ovarian cancer patients. Ann Oncol 13: 258–66

    Article  CAS  PubMed  Google Scholar 

  31. Piccart MJ, Green JA, Lacave AJ et al. (2000) Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 18: 1193–202

    CAS  PubMed  Google Scholar 

  32. Markman M, Hall J, Spitz D et al. (2002) Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20: 2365–9

    Article  CAS  PubMed  Google Scholar 

  33. Williams CJ (2000) Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev: CD001034

    Google Scholar 

  34. Williams C, Simera I (2004) Tamoxifen for relapse of ovarian cancer. Cochran Rev Abstract http://www.medscape.com/viewarticle/485445

    Google Scholar 

  35. Gronlund B, Hansen HH, Hogdall C et al. (2002) Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer 95: 1656–62

    Article  CAS  PubMed  Google Scholar 

  36. ten Bokkel Huinink W, Lane SR, Ross GA (2004) Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15: 100–3

    Google Scholar 

  37. Levy T, Inbar M, Menczer J et al. (2004) Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 95: 686–90

    Article  CAS  PubMed  Google Scholar 

  38. Sorensen P, Hoyer M, Jakobsen A et al. (2001) Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol 81: 58–62

    CAS  PubMed  Google Scholar 

  39. Chollet P, Bensmaine MA, Brienza S et al. (1996) Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7: 1065–70

    CAS  PubMed  Google Scholar 

  40. George MJ, Heron JF, Kerbrat P et al. (1989) Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers. Semin Oncol 16: 30–2

    CAS  PubMed  Google Scholar 

  41. Markman M, Webster K, Zanotti K et al. (2004) Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol 93: 699–701

    CAS  PubMed  Google Scholar 

  42. Fracasso PM, Rodriguez LC, Herzog TJ et al. (2003) Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies. Cancer 98: 610–7

    Article  CAS  PubMed  Google Scholar 

  43. Seiden MV, Ng SW, Supko JG et al. (2002) A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin Cancer Res 8: 691–7

    CAS  PubMed  Google Scholar 

  44. Bolis G, Parazzini F, Scarfone G et al. (1999) Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and-resistant ovarian cancer. Gynecol Oncol 72: 60–4

    Article  CAS  PubMed  Google Scholar 

  45. Shaheen M, Stender MJ, McClean JW et al. (2004) Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study. Am J Clin Oncol 27: 229–31

    CAS  PubMed  Google Scholar 

  46. van der Burg ME, Vergote I, Burger C et al. (2004) Phase II study of weekly paclitaxel carboplatin in the treatment of progressive ovarian cancer. J Clin Oncol 22: 463s (abs5058)

    Google Scholar 

  47. Aravantinos G, Bafaloukos D, Fountzilas G et al. (2003) Phase II study of docetaxelvinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol 14: 1094–9

    Article  CAS  PubMed  Google Scholar 

  48. Sundar S, Symonds RP, Decatris MP et al. (2004) Phase II trial of Oxaliplatin and 5-fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecol Oncol 94: 502–8

    Article  CAS  PubMed  Google Scholar 

  49. Pectasides D, Pectasides M, Farmakis D et al. (2004) Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol 95: 165–72

    Article  CAS  PubMed  Google Scholar 

  50. Dohollou N, Weber B, Geay J et al. (2003) Gemcitabine and oxaliplatin in patients with recurrent advanced ovarian cancer in early progression: a GINECO phase II trial, 39th annual meeting Am Soc Clin Oncol, ASCO (abs 1813): 451

    Google Scholar 

  51. Raspagliesi F, Zanaboni F, Vecchione F, et al: Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. Oncology 67: 376–81, 2004

    Article  CAS  PubMed  Google Scholar 

  52. Faivre S, Kalla S, Cvitkovic E et al. (1999) Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann Oncol 10: 1125–8

    Article  CAS  PubMed  Google Scholar 

  53. van der Burg ME, de Wit R, van Putten WL et al. (2002) Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 86: 19–25

    PubMed  Google Scholar 

  54. Tewari D, Monk BJ, Hunter M et al. (2004) Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest New Drugs 22: 475–80

    Article  CAS  PubMed  Google Scholar 

  55. Garcia AA, O’Meara A, Bahador A et al. (2004) Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol Oncol 93: 493–8

    Article  CAS  PubMed  Google Scholar 

  56. Bruzzone M, Mencobini M, Mammoliti S et al. (2004) Second line chemotherapy with gemcitabine and vepesid in platinum resistant advanced ovarian cancer patients. J Clin Oncol 22: 469s (abs 5082)

    Google Scholar 

  57. Ganem G, Gladieff L, Guastalla J et al. (1998) Sequential toptecan and Etoposide in pretreated ovarian cancer patients: a Gineco phase II study, in ASCO (ed): 34th meeting of Am Soc Clin Oncol (abs1371)

    Google Scholar 

  58. Sood AK, Lush R, Geisler JP et al. (2004) Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res 10: 6080–5

    Article  CAS  PubMed  Google Scholar 

  59. Chiara S, Tognoni A, Pastrone I et al. (2004) Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. Gynecol Oncol 93: 474–8

    Article  CAS  PubMed  Google Scholar 

  60. Aoki Y, Kurata H, Watanabe M et al. (2004) Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer. Am J Clin Oncol 27: 461–4

    CAS  PubMed  Google Scholar 

  61. Zanaboni F, Scarfone G, Presti M et al. (1991) Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin in combination with epirubicin or etoposide. Gynecol Oncol 43: 24–8

    Article  CAS  PubMed  Google Scholar 

  62. Kerbusch T, Groenewegen G, Mathot RA et al. (2004) Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. Br J Cancer 90: 2268–77

    CAS  PubMed  Google Scholar 

  63. Gronlund B, Hogdall C, Christensen IJ et al. (2004) Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum? Gynecol Oncol 94: 409–15

    Article  CAS  PubMed  Google Scholar 

  64. Gronlund B, Hogdall C, Hilden J et al. (2004) Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during secondline chemotherapy of ovarian carcinoma? J Clin Oncol 22: 4051–8

    Article  PubMed  Google Scholar 

  65. Markman M, Rothman R, Hakes T et al. (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389–93

    CAS  PubMed  Google Scholar 

  66. Kavanagh J, Tresukosol D, Edwards C et al. (1995) Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13: 1584–8

    CAS  PubMed  Google Scholar 

  67. Bookman MA (1999) Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 4: 87–94

    CAS  PubMed  Google Scholar 

  68. Parmar MK, Ledermann JA, Colombo N et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099–106

    CAS  PubMed  Google Scholar 

  69. Pujade-Lauraine E, Paraiso D, Joly F et al. (2003) Is there a role for platinum in the treatment of patients with “ platinum-resistant ” relapsed advanced ovarian cancer? a GINECO study (abs1811): 451

    Google Scholar 

  70. Leitao MM, Jr, Hummer A, Dizon DS et al. (2003) Platinum retreatment of platinumresistant ovarian cancer after nonplatinum therapy. Gynecol Oncol 91: 123–9

    CAS  PubMed  Google Scholar 

Download references

Authors
  1. B. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France

About this chapter

Cite this chapter

Weber, B. (2006). Traitement médical des rechutes (récidives) précoces. In: Les cancers ovariens. Abord clinique. Springer, Paris. https://doi.org/10.1007/2-287-30921-7_29

Download citation

  • DOI: https://doi.org/10.1007/2-287-30921-7_29

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25168-9

  • Online ISBN: 978-2-287-30921-2

Publish with us

Policies and ethics

Search

Navigation